30 closest matches · ranked by relevance
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
Chronic Kidney Disease
Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Chronic Kidney Diseases
Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
End-Stage Renal Disease · Stage 5 Chronic Kidney Disease
Primary: Cmax of Telavancin — 33.1; 38.1 mcg/mL
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: Number of Adverse Events (AE) — 109; 50; 63 participants
Chronic Renal Insufficiency · Proteinuria
Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Anemia
Primary: Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1) — 23 participants
Anemia
Primary: Percentage of Participants Reaching a Hemoglobin (Hb) Value of Greater Than (>) 100 and Less Than (<) 120 Grams Per Liter (gm/L) at Month 6 Before Inclusion — 56.8…
Chronic Kidney Disease
Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale
Secondary Hyperparathyroidism · Chronic Kidney Disease Stage V · Cardiac Morbidity
Primary: Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range — 28.4; 43.3; 35.8; 38.8 percentage of participants
Chronic Kidney Disease
Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
End-stage Renal Disease (ESRD)
Primary: Peak Oxygen Consumption — 3.07 ml/min/kg
Chronic Kidney Diseases
Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338
Hypertension
Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg
Chronic Kidney Disease · Hypertension
Primary: Change in Urinary Albumin Excretion From Baseline to 4 Months — -28.6; -5.6 mg/g — p=0.17
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Chronic Kidney Disease
Primary: Change in Subjective Units of Distress Scale (SUDS) Score — 2.92; 3.12 score on a scale